Video Experimental Relacionado
Updated: Aug 4, 2026
07:13
Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation
Published on: January 7, 2019
Inhibición persistente de las plaquetas durante el tratamiento continuo con nitroglicerina a pesar de la tolerancia
1Department of Medicine, Montreal Heart Institute, University of Montreal Medical School, Canada.
Circulation
|March 4, 1997
Resumen
La terapia continua con nitroglicerina reduce consistentemente la deposición y agregación plaquetaria, incluso cuando se desarrolla tolerancia hemodinámica. Esto indica que los efectos antiplaquetarios sostenidos son cruciales para la salud cardiovascular.
Área de la Ciencia:
- Farmacología Cardiovascular Farmacología Cardiovascular
- La hemodinámica es la hemodinámica.
- Biología plaquetaria Biología plaquetaria.
Sus antecedentes:
- La nitroglicerina exhibe propiedades antiplaquetarias en estudios tanto en animales como en humanos.
- Se sabe que la tolerancia a los efectos hemodinámicos de la nitroglicerina ocurre con la terapia continua.
- La persistencia del efecto antiplaquetario de la nitroglicerina durante el tratamiento continuo sigue sin estar clara.
Objetivo del estudio:
- Investigar si se desarrolla tolerancia a los efectos antiplaquetarios del tratamiento continuo con nitroglicerina.
- Para evaluar el impacto de la administración prolongada de nitroglicerina en la función plaquetaria y la deposición.
Principales métodos:
- Los medios aórticos porcinos estuvieron expuestos a sangre arterial de cerdos de control y cerdos que recibieron parches de nitroglicerina continuos (0,8 mg/h).
- La deposición de plaquetas en los medios aórticos se midió utilizando plaquetas autólogas etiquetadas con 51Cr en condiciones de alto cizallamiento.
- Se evaluó la agregación plaquetaria inducida por la trombina y los niveles intraplaquetarios de monofosfato cíclico de guanosina (cGMP).
Principales resultados:
- El tratamiento continuo con nitroglicerina redujo significativamente la deposición de plaquetas en los medios aórticos a las 3, 24 y 48 horas en comparación con el valor basal.
- La agregación plaquetaria inducida por la trombina disminuyó significativamente a lo largo del período de tratamiento de 48 horas.
- La administración de nitroglicerina condujo a un aumento de los niveles intraplaquetarios de GMPc, lo que indica una acción farmacológica sostenida.
Conclusiones:
- La terapia continua con nitroglicerina mantiene su eficacia antiplaquetaria a pesar del desarrollo de tolerancia a sus efectos hemodinámicos.
- El estudio demuestra la inhibición persistente de la función plaquetaria y la deposición en las paredes arteriales lesionadas con el uso sostenido de nitroglicerina.
- Estos hallazgos resaltan la importancia de la acción antiplaquetaria de la nitroglicerina en el manejo de las afecciones cardiovasculares.
Videos de Conceptos Relacionados
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...